Get in touch

913-851-0877 info@mptbiotechs.com

Services

Our Services

What Service We Offer

Two of the protein boxes missed. Protein AG, Streptavidin, please add them. Those are in dropdown but not in main landing page.

coronavirus-vaccine-research-

Recombinant Protein A

Proprietary recombinant Protein A is produced using our proprietary MPTxpress solid-state E. coli expression system. This Protein A functions essentially the same as native Protein A.

male-scientist-chemist-working-with-microscope-in-pharmaceutica

Recombinant Protein L

Recombinant Protein L is expressed by MicroProtein Technologies in E.coli using its MPTxpress upstream platform with innovative purification methods.

science-research-innovation-development-and-production-concept-cosmetology-worker-manufacturing

Recombinant Protein G

The gene we selected to use for the production of Protein G originated from Streptococcus Strain G148, and was cloned and expressed in our proprietary strain of Escherichia coli.

young-students-of-chemistry-working-in-laboratory

Recombinant Protein AG

Our recombinant Protein A/G is a fusion protein that comprises of a total of 7 IgG-binding domains EDABC-C2C3. This fusion protein combines the active Fc-binding domains of Protein A and Protein G that are contained in the recombinant sequence.

wd

Carrier-Free Human Interleukin-2

Interleukin-2 (IL-2) is one of a family of polypeptides that mediate interactions
between leukocytes. It is a T-cell growth factor.

ww

Streptavidin

Streptavidin is a biotin-binding protein found in culture broth of the bacterium
Streptomyces avidin. Streptavidin binds 4 moles of biotin per mole of protein
with a remarkably high affinity.

young-students-of-chemistry-working-in-laboratory

Contract Research Organization (CRO) -

During the research and development of protein-based therapeutics, finding the
optimal conditions for protein production is often a time-consuming and laborintensive process.

wd

Contract Manufacturing Organization (CMO)

The R&D pipeline for new drugs has changed considerably over the past decade.
Once dominated by big pharma and small molecules, today’s pipeline is
increasingly populated with small and emerging biotech companies developing
large molecules, or biologics, which now make up nearly 40% of the active R&D
pipeline globally.

Testimonials

We Are Trusted Over 16+ Countries Worldwide

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua

    Joss Dowling
    Joss Dowling

    Entrepreneur

    Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua

      Addie Hickman
      Addie Hickman

      Manager

      Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua

        Aniya Lester
        Aniya Lester

        CEO Brand

        Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua

          Juliet Bond
          Juliet Bond

          Entrepreneur